397 related articles for article (PubMed ID: 30572736)
21. Progress and contrasts of the development of tivozanib for therapy of kidney cancer.
Gupta S; Fishman M
Expert Opin Pharmacother; 2011 Dec; 12(18):2915-22. PubMed ID: 22098229
[TBL] [Abstract][Full Text] [Related]
22. VEGF inhibitors in metastatic renal cell carcinoma: current therapies and future perspective.
Choueiri TK
Curr Clin Pharmacol; 2011 Aug; 6(3):164-8. PubMed ID: 21827394
[TBL] [Abstract][Full Text] [Related]
23. First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy.
Tannir N; Hammers H; Amin A
Curr Med Res Opin; 2018 May; 34(5):825-831. PubMed ID: 29297707
[TBL] [Abstract][Full Text] [Related]
24. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.
Agarwala SS; Case S
Oncologist; 2010; 15(3):236-45. PubMed ID: 20215359
[TBL] [Abstract][Full Text] [Related]
25. Cabozantinib for the treatment of renal cell carcinoma.
Escudier B; Lougheed JC; Albiges L
Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
[TBL] [Abstract][Full Text] [Related]
26. [Medical treatment of renal cell carcinoma].
Guy L; Bay JO; Bastide C; Mahammedi H; Bruyere F; Karsenty G
Prog Urol; 2013 Nov; 23(15):1225-37. PubMed ID: 24183081
[TBL] [Abstract][Full Text] [Related]
27. Understanding the importance of smart drugs in renal cell carcinoma.
Patard JJ; Rioux-Leclercq N; Fergelot P
Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
[TBL] [Abstract][Full Text] [Related]
28. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
29. Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma.
Li W; Feng C; Di W; Hong S; Chen H; Ejaz M; Yang Y; Xu TR
Eur J Med Chem; 2020 Aug; 200():112482. PubMed ID: 32492594
[TBL] [Abstract][Full Text] [Related]
30. Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.
Reed JP; Posadas EM; Figlin RA
Expert Rev Anticancer Ther; 2019 Mar; 19(3):259-271. PubMed ID: 30669895
[TBL] [Abstract][Full Text] [Related]
31. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Mulders P
BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
[TBL] [Abstract][Full Text] [Related]
33. Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors.
Desai A; Small EJ
Future Oncol; 2019 Jul; 15(20):2337-2348. PubMed ID: 31184937
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
[TBL] [Abstract][Full Text] [Related]
35. Tivozanib: a new treatment option for renal cell carcinoma.
Saes L; Eskens FALM
Drugs Today (Barc); 2017 Nov; 53(11):609-618. PubMed ID: 29451277
[TBL] [Abstract][Full Text] [Related]
36. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.
Zakharia Y; Zakharia K; Rixe O
Expert Opin Drug Discov; 2015; 10(8):925-35. PubMed ID: 26039031
[TBL] [Abstract][Full Text] [Related]
37. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
38. Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".
Alonso-Gordoa T; García-Bermejo ML; Grande E; Garrido P; Carrato A; Molina-Cerrillo J
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999623
[TBL] [Abstract][Full Text] [Related]
39. Targeted agents for the treatment of advanced renal cell carcinoma.
Stadler WM
Cancer; 2005 Dec; 104(11):2323-33. PubMed ID: 16240452
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis.
Iacovelli R; Sternberg CN; Porta C; Verzoni E; de Braud F; Escudier B; Procopio G
Curr Drug Targets; 2015; 16(2):164-70. PubMed ID: 25410406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
